Exact Sciences(EXAS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

EXAS Exact Sciences

Pre-Market Trading 03-27 04:01:19 EDT

44.92

-0.75

-1.64%

High46.29	Low44.78	Vol1.37M
Open45.68	D1 Closing45.67	Amplitude3.31%
Mkt Cap8.34B	Tradable Cap8.28B	Total Shares185.76M
T/O62.18M	T/O Rate0.75%	Tradable Shares184.42M
P/B3.47	ROE-37.09%	EPS-5.59
52wk High79.62	52wk Low40.62	P/E-8.04
Dividend0.00	Div.Yield0.00	ROA-1.87%

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"EXAS","market":"US","secType":"STK","nameCN":"Exact Sciences","latestPrice":44.92,"timestamp":1743019200000,"preClose":45.67,"halted":0,"volume":1374090,"delay":0,"floatShares":184415998,"shares":185755406,"eps":-5.59,"marketStatus":"Pre-Market Trading","change":-0.75,"latestTime":"03-27 04:01:16 EDT","open":45.68,"high":46.29,"low":44.78,"amount":62180974.74684,"amplitude":0.033063,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.59,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1743082200000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":980917200000,"exchange":"NASDAQ","adjPreClose":44.92,"postHourTrading":{"tag":"盘后","latestPrice":44.9,"preClose":44.92,"latestTime":"18:14 EDT","volume":80188,"amount":3603050.89,"timestamp":1743027271753},"volumeRatio":0.741597665865349,"impliedVol":0.5423,"impliedVolPercentile":0.4137},"requestUrl":"/m/hq/s/EXAS/wiki","defaultTab":"wiki","newsList":[{"id":"2521301237","title":"Exact Sciences (EXAS) Down 10.6% Since Last Earnings Report: Can It Rebound?","url":"https://stock-news.laohu8.com/highlight/detail?id=2521301237","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521301237?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 23:30","pubTimestamp":1742571029,"startTime":"0","endTime":"0","summary":"A month has gone by since the last earnings report for Exact Sciences . Shares have lost about 10.6% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Exact Sciences due for a breakout?Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.It turns out, estimates revision have trended upward during the past month.The consensus estimate has shifted -20.69% due to these changes.Exact Sciences is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Exelixis , a stock from the same industry, has gained 6%. The company reported its results for the quarter ended December 2024 more than a month ago.Exact Sciences Corporation  : Free Stock Analysis Report. This article originally published on Zacks Investment Research .","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exact-sciences-exas-down-10-153029918.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["EXEL","EXAS"],"gpt_icon":0},{"id":"2520645715","title":"1 Healthcare Stock on Our Watchlist and 2 to Turn Down","url":"https://stock-news.laohu8.com/highlight/detail?id=2520645715","media":"StockStory","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520645715?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 21:03","pubTimestamp":1742475824,"startTime":"0","endTime":"0","summary":"Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The result?Over the past six months, the industry has tumbled by 8.4%. This drop was disappointing since the S&P 500 stood firm.The elite companies can churn out earnings growth under any circumstance, however, and our mission at StockStory is to help you find them. Keeping that in mind, here is one resilient healthcare stock at the top of our wish list and two that may face trouble.Revenue growth over the past five years was nullified by the company’s new share issuances as its earnings per share fell by 19% annually. Poor free cash flow margin of 0.3% for the last five years limits its freedom to invest in growth initiatives, execute share buybacks, or pay dividends. Average constant currency growth of 15.3% over the past two years demonstrates its abili","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/1-healthcare-stock-watchlist-2-130344797.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["EVH","HCSG","LU1861558580.USD","BK4139","BK4585","LU2324357040.USD","GH","LU0053671581.USD","EXAS","BK4535","BK4588","BK4196","LU0266013472.USD","LU1861559042.SGD","BK4551","BK4167","BK4548","BK4137"],"gpt_icon":1},{"id":"2520451548","title":"Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack","url":"https://stock-news.laohu8.com/highlight/detail?id=2520451548","media":"StockStory","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520451548?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 17:09","pubTimestamp":1742461785,"startTime":"0","endTime":"0","summary":"Wrapping up Q4 earnings, we look at the numbers and key takeaways for the immuno-oncology stocks, including Natera  and its peers.Over the next few years, immuno-oncology companies, which harness the immune system to fight illnesses such as cancer, faces strong tailwinds from advancements in precision medicine  and growing demand for treatments targeting rare diseases. However, headwinds such as rising scrutiny over drug pricing, regulatory unknowns, and competition from larger, more resourced pharmaceutical companies could weigh on growth.The 4 immuno-oncology stocks we track reported a strong Q4. As a group, revenues beat analysts’ consensus estimates by 3.5%.Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 6.9% since the latest earnings results.Founded in 2003 as Gene Security Network before rebranding in 2012, Natera  develops and commercializes genetic tests for prenatal screening, cancer detection, and organ transplant monitoring","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/natera-nasdaq-ntra-q4-earnings-090945808.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["REGN","NDAQ","EXAS","NTRA",".IXIC","INCY"],"gpt_icon":0},{"id":"2520564941","title":"BTIG Sticks to Its Buy Rating for Exact Sciences (EXAS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2520564941","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520564941?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 17:57","pubTimestamp":1742291872,"startTime":"0","endTime":"0","summary":"BTIG analyst Mark Massaro reiterated a Buy rating on Exact Sciences (EXAS – Research Report) yesterday and set a price target of $65.00. The compan...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/btig-sticks-to-its-buy-rating-for-exact-sciences-exas-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/btig-sticks-to-its-buy-rating-for-exact-sciences-exas-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EXAS"],"gpt_icon":0},{"id":"2519868705","title":"BUZZ-RBC initiates Exact Sciences coverage with 'perform' rating on oncology screening strength","url":"https://stock-news.laohu8.com/highlight/detail?id=2519868705","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519868705?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 02:36","pubTimestamp":1741890963,"startTime":"0","endTime":"0","summary":"BUZZ-RBC initiates Exact Sciences coverage with 'perform' rating on oncology screening strength** Brokerage RBC Capital Markets initiates coverage on Exact Sciences EXAS.O with \"perform\" rating** Brokerage sets PT at $52, representing over 12% upside to the stock's last close** \"By building market awareness for Cologuard while successfully navigating the FDA approval process and payor reimbursement requirements, EXAS has established itself as a leader in the oncology Screening sector of Liquid Biopsy\" - RBC Capital Markets** Brokerage adds that low switching costs and the appeal of a blood-based test may make their  moat difficult to defend** Says company will need to navigate competitive pricing from new entrants in colorectal cancer screening** Twenty-three of 27 brokerages rate stock \"buy\" or higher, and four \"hold\"; with a median PT of $69.7, according to data compiled by LSEG** Stock is down over 24% YTD, including session moves; EXAS shed 24% in 2024  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nL4N3PW1FS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXAS"],"gpt_icon":0},{"id":"2519833815","title":"Exact Sciences Initiated at Sector Perform by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2519833815","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519833815?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 19:44","pubTimestamp":1741866240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EXAS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 13, 2025 07:44 ET (11:44 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0266013472.USD","LU1861558580.USD","LU2324357040.USD","BK4588","EXAS","BK4548","BK4585","BK4139","BK4207","LU1861559042.SGD"],"gpt_icon":0},{"id":"2519882853","title":"RBC Initiates Exact Sciences at Sector Perform With $52 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2519882853","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519882853?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 18:38","pubTimestamp":1741862335,"startTime":"0","endTime":"0","summary":"Exact Sciences (EXAS) has an average rating of buy and mean price target of $70.18, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major bank","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EXAS"],"gpt_icon":0},{"id":"2517439780","title":"3 Top Cancer Biotechs to Keep An Eye On in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2517439780","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517439780?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 21:22","pubTimestamp":1741353720,"startTime":"0","endTime":"0","summary":"The landscape of cancer treatment is undergoing a transformative shift as there is a rising demand for targeted, less toxic cancer medicines.The cancer field has seen significant advancements with the emergence of new cancer treatments likeimmunotherapy, targeted therapies and personalized vaccines. Immune-based oncology treatments range from checkpoint inhibitors and CAR-T cell therapies to cancer vaccines and oncolytic viruses. These work by harnessing the body’s own immune system to attack cancer cells.Targeted therapies specifically target the genetic mutations driving a particular cancer, thereby offering more precise treatment options with fewer side effects than traditional chemotherapy treatment. Personalized cancer vaccines use a patient's own tumor proteins to trigger an immune response against cancer cells.While decades of research and advanced treatments have prolonged the lives of cancer patients in the last 20 years, a possible cure remains elusive. As the world at large ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-top-cancer-biotechs-keep-132200662.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0061475181.USD","LU0211331839.USD","LU0320765992.SGD","LU0965509010.AUD","BK4516","LU0256863902.USD","LU2089283258.USD","NVS","LU0738911758.USD","LU1720051108.HKD","LU1244550577.SGD","LU0417517546.SGD","LU2417539215.USD","LU0109394709.USD","LU2112291526.USD","LU1037948897.HKD","LU2106854487.HKD","LU0471298694.HKD","GLUE","BK4566","LU0306806265.USD","LU1551013342.USD","LU1989772923.USD","IE00BK4W5L77.USD","SGXZ57979304.SGD","LU0965509101.SGD","EXAS","IE00B19Z3B42.SGD","SG9999001440.SGD","LU0965509283.SGD","LU2357305700.SGD","LU1720051017.SGD","LU2087621335.USD","ABBV","IE00BBT3K403.USD","LU0234570918.USD","LU0238689110.USD","LU1934455277.USD","IE00BJT1NW94.SGD","LU1623119135.USD","IE00BK4W5M84.HKD","SGXZ31699556.SGD","IE00BVYPNW00.USD","LU1868836757.USD","LU0949170772.SGD","LU0203347892.USD","AZN","LU0882574055.USD"],"gpt_icon":1},{"id":"2516671764","title":"Here’s What Led Artisan Mid Cap Fund to Trim Exact Sciences Corporation (EXAS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2516671764","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516671764?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 22:00","pubTimestamp":1741096842,"startTime":"0","endTime":"0","summary":"Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. In the fourth quarter, the fund’s Investor Class fund ARTMX returned 5.11%, Advisor Class fund APDMX posted a return of 5.14%, and Institutional Class fund APHMX returned 5.14%, compared to an 8.14% return for the Russell Midcap Growth Index. US equities achieved solid Q4 gains, concluding a strong year. Following Donald Trump’s election win, optimism surged over deregulation and tax cuts. However, concerns about inflation from proposed tariffs and immigration policies emerged in December, introducing market volatility. Despite this, markets ended 2024 with strong gains, marking one of the best two-year performance stretches in decades. In addition, please check the fund’s top five holdings to know its best picks in 2024.Exact Sciences Corporation  is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/led-artisan-mid-cap-fund-140042193.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PSQ","MNQmain","USJW.SI","BK4548","LU2324357040.USD",".IXIC","TQQQ","LU0266013472.USD","NQmain","BK4585","BK4588","LU1861558580.USD","QID","QLD","SQQQ","LU1861559042.SGD","USAW.SI","BK4139","NVIW.SI","EXAS","TSYW.SI"],"gpt_icon":1},{"id":"2516339698","title":"Exact Sciences Corporation (EXAS): Among the Cash-Rich Mid Cap Stocks to Buy Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2516339698","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516339698?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 07:48","pubTimestamp":1741045719,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Cash-Rich Mid Cap Stocks To Buy Now.In this article, we are going to take a look at where Exact Sciences Corporation  stands against the other cash-rich mid cap stocks.For this article, we used the Finviz stock screener to identify cash-rich mid-cap stocks. We applied a filter to select companies with market caps between $2 billion and $10 billion. Additionally, we used a current ratio  filter of over 2 to identify stocks with strong current assets. CR is a company’s current assets divided by its current liabilities. If the CR is over 1, it means the company has more assets than liabilities, usually because of high cash reserves, receivables, or inventory. After filtering, we manually searched for companies with cash and cash equivalents exceeding $1 billion as of December 31, 2024 and selected the 10 stocks with the highest cash reserves. The list below is ranked in ascending order based on cash and cash equivalents. We have also included hedge fu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exact-sciences-corporation-exas-among-234839922.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["EXAS","NQmain","BK4585","NVIW.SI","PSQ","BK4588","QLD","CR","TSYW.SI","BK4139",".IXIC","USAW.SI","LU0266013472.USD","LU1861558580.USD","MNQmain","BK4161","LU1861559042.SGD","TQQQ","BK4548","LU2324357040.USD","QID","SQQQ","USJW.SI"],"gpt_icon":1},{"id":"2514865707","title":"Exact Sciences Is Maintained at Overweight by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2514865707","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514865707?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 02:03","pubTimestamp":1740592980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EXAS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 26, 2025 13:03 ET (18:03 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXAS"],"gpt_icon":0},{"id":"2514085175","title":"Hologic Wins Key Approvals Post Q1 Results: Buy or Hold HOLX Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2514085175","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514085175?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 21:03","pubTimestamp":1740574980,"startTime":"0","endTime":"0","summary":"Last week, Hologic HOLX earned two key regulatory approvals. The company’s AffirmContrast Biopsy software has earned the CE Mark, having previously been cleared by the FDA in October 2020. Meanwhile, the Aptima SARS-CoV-2 assay, initially granted Emergency Use Authorization status in May 2020, has now achieved the FDA’s 510k clearance.These advancements come after Hologic’s fiscal 2025 first-quarter report, released earlier this month, which reflected strengths and challenges within the divisions and from the broader macroeconomy. Since the earnings announcement, HOLX shares have plunged 10.4%, finishing at $65.01 yesterday.The company’s Aptima SARS-CoV-2 Assay is anin vitrodiagnostic test that detects SARS-CoV-2 RNA from nasopharyngeal  or nasal swab samples obtained from people exhibiting signs and symptoms of a respiratory tract infection. With the virus now in an endemic state, full FDA clearance ensures that laboratories and clinicians can still rely on the test to make informed d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hologic-wins-key-approvals-post-130300697.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","LU0266013472.USD","LU2433249047.HKD","LU2125909593.SGD","LU2125909247.SGD","LU1923623000.USD","LU2324357040.USD","BK4121","BK4585","BK4159","QGEN","BK4082","LU0823416689.USD","BK4212","HOLX","BK4139","LU1951198990.SGD","CAGR","LU1951200564.SGD","EXAS","LU1861558580.USD","LU1861559042.SGD","POST","BK4548","LU1923622614.USD"],"gpt_icon":0},{"id":"2514762834","title":"Exact Sciences price target lowered to $70 from $75 at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2514762834","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514762834?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 20:40","pubTimestamp":1740573655,"startTime":"0","endTime":"0","summary":"Piper Sandler lowered the firm’s price target on Exact Sciences (EXAS) to $70 from $75 following quarterly results. The firm keeps an Overweight ra...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/exact-sciences-price-target-lowered-to-70-from-75-at-piper-sandler?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/exact-sciences-price-target-lowered-to-70-from-75-at-piper-sandler?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EXAS"],"gpt_icon":0},{"id":"2514309789","title":"Exploring Three High Growth Tech Stocks In The United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2514309789","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514309789?lang=en_us&edition=full_marsco","pubTime":"2025-02-25 22:02","pubTimestamp":1740492148,"startTime":"0","endTime":"0","summary":"Over the last 7 days, the United States market has experienced a 3.0% decline, though it remains up by 18% over the past year with earnings forecasted to grow annually by 14%. In this context of fluctuating yet promising growth, identifying high growth tech stocks requires careful consideration of their potential for innovation and scalability in alignment with broader market trends.Top 10 High Growth Tech Companies In The United States. Click here to see the full list of 227 stocks from our US High Growth Tech and AI Stocks screener.Operations: The company generates revenue primarily from its biotechnology segment, which contributed $2.76 billion. It focuses on cancer screening and diagnostic test products both domestically and internationally.Operations: Bel Fuse Inc. generates revenue through three primary segments: Power Solutions and Protection, Connectivity Solutions, and Magnetic Solutions, with the Power Solutions and Protection segment contributing $245.55 million. The company","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exploring-three-high-growth-tech-140228076.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0053671581.USD","LU2324357040.USD","BK4588","SMCI","LU0266013472.USD","LU1861558580.USD","BELFB","LU1861215975.USD","BK4170","BELFA","BK4211","UBCP","EXAS","BK4548","LU1861220033.SGD","BK4543","BK4139","BK4585","LU1861559042.SGD"],"gpt_icon":1},{"id":"1182320766","title":"Stock Track | Exact Sciences Soars 5.05% on Monday Amid Investor Conference Participation and Analyst Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1182320766","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182320766?lang=en_us&edition=full_marsco","pubTime":"2025-02-25 01:42","pubTimestamp":1740418961,"startTime":"0","endTime":"0","summary":"Exact Sciences Corp. , a leading provider of cancer screening and diagnostic tests, saw its stock soar 5.05% on Monday during the trading session. This upward movement came as the company announced its participation in two upcoming investor conferences and received a positive analyst rating.Exact Sciences revealed that its management team will present at the TD Cowen Health Care Conference in Boston on March 3rd and the Raymond James Institutional Investors Conference in Orlando on March 4th. Du","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | Exact Sciences Soars 5.05% on Monday Amid Investor Conference Participation and Analyst Rating","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["EXAS"],"gpt_icon":0},{"id":"2513720604","title":"Exact Sciences Is Maintained at Sector Outperform by Scotiabank","url":"https://stock-news.laohu8.com/highlight/detail?id=2513720604","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513720604?lang=en_us&edition=full_marsco","pubTime":"2025-02-24 22:55","pubTimestamp":1740408900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EXAS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 24, 2025 09:55 ET (14:55 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXAS"],"gpt_icon":0},{"id":"2513077749","title":"Exact Sciences to Participate in March Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2513077749","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513077749?lang=en_us&edition=full_marsco","pubTime":"2025-02-24 19:00","pubTimestamp":1740394800,"startTime":"0","endTime":"0","summary":"MADISON, Wis., February 24, 2025----Exact Sciences Corp. , a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast.TD Cowen Health Care Conference, BostonFireside chat on Monday, March 3, 2025 at 10:30 a.m. ET. A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard and Oncotype tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on X @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exact-sciences-participate-march-investor-110000301.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0266013472.USD","LU1861558580.USD","LU1861559042.SGD","BK4548","BK4588","EXAS","LU2324357040.USD","BK4585","BK4139"],"gpt_icon":0},{"id":"2513121684","title":"What's Going On With Cancer Diagnostic Firm Guardant Health On Friday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2513121684","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513121684?lang=en_us&edition=full_marsco","pubTime":"2025-02-22 02:33","pubTimestamp":1740162818,"startTime":"0","endTime":"0","summary":"Guardant Health beat Q4 estimates with a smaller EPS loss and strong revenue growth. Analysts raised price targets, citing momentum and solid financials.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/02/43890342/whats-going-on-with-cancer-diagnostic-firm-guardant-health-on-friday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","LU2324357040.USD","BK4196","EXAS","BK4535","LU1861559042.SGD","BK4588","BK4139","BK4548","LU0266013472.USD","LU1861558580.USD","GH","BK4585"],"gpt_icon":0},{"id":"2513261978","title":"Exact Sciences Full Year 2024 Earnings: EPS Misses Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2513261978","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513261978?lang=en_us&edition=full_marsco","pubTime":"2025-02-21 19:50","pubTimestamp":1740138646,"startTime":"0","endTime":"0","summary":"NasdaqCM:EXAS Earnings and Revenue Growth February 21st 2025. All figures shown in the chart above are for the trailing 12 month  period. Revenue was in line with analyst estimates. Earnings per share  missed analyst estimates significantly.Looking ahead, revenue is forecast to grow 9.5% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US.The company's shares are down 2.1% from a week ago.Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We have a graphic representation of Exact Sciences' balance sheet and an in-depth analysis of the company's financial position.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exact-sciences-full-2024-earnings-115046572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["EXAS"],"gpt_icon":0},{"id":"1135485001","title":"Stock Track | Exact Sciences Plummets 7.25% in Pre-Market as Analysts Cut Price Targets on Growth Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=1135485001","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135485001?lang=en_us&edition=full_marsco","pubTime":"2025-02-20 22:43","pubTimestamp":1740062625,"startTime":"0","endTime":"0","summary":"Exact Sciences  stock plummeted 7.25% in the pre-market trading session on Thursday, following multiple price target cuts from Wall Street analysts on concerns over the company's growth prospects.Barclays analyst Luke Sergott lowered the firm's price target on EXAS to $65 from $70, while maintaining an Overweight rating on the stock. Sergott cited the company's Q4 results and guidance as factors behind the price target reduction. Similarly, BTIG cut its price target on the molecular diagnostics ","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["EXAS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.exactsciences.com","stockEarnings":[{"period":"1week","weight":-0.0171},{"period":"1month","weight":-0.124},{"period":"3month","weight":-0.2185},{"period":"6month","weight":-0.319},{"period":"1year","weight":-0.3115},{"period":"ytd","weight":-0.2006}],"compareEarnings":[{"period":"1week","weight":0.0026},{"period":"1month","weight":-0.0479},{"period":"3month","weight":-0.0545},{"period":"6month","weight":-0.005},{"period":"1year","weight":0.096},{"period":"ytd","weight":-0.0298}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.090028},{"month":2,"riseRate":0.28,"avgChangeRate":-0.066007},{"month":3,"riseRate":0.56,"avgChangeRate":0.071719},{"month":4,"riseRate":0.416667,"avgChangeRate":0.01784},{"month":5,"riseRate":0.541667,"avgChangeRate":0.055726},{"month":6,"riseRate":0.625,"avgChangeRate":0.093567},{"month":7,"riseRate":0.375,"avgChangeRate":-0.013807},{"month":8,"riseRate":0.416667,"avgChangeRate":0.011798},{"month":9,"riseRate":0.5,"avgChangeRate":-0.002091},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.04237},{"month":11,"riseRate":0.583333,"avgChangeRate":0.016212},{"month":12,"riseRate":0.583333,"avgChangeRate":0.05644}],"exchange":"NASDAQ","name":"Exact Sciences","nameEN":"Exact Sciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Exact Sciences(EXAS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Exact Sciences(EXAS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Exact Sciences,EXAS,Exact Sciences股票,Exact Sciences股票老虎,Exact Sciences股票老虎国际,Exact Sciences行情,Exact Sciences股票行情,Exact Sciences股价,Exact Sciences股市,Exact Sciences股票价格,Exact Sciences股票交易,Exact Sciences股票购买,Exact Sciences股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Exact Sciences(EXAS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Exact Sciences(EXAS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction